Logo
x

Search

Subscribe Now

hemophilia b

PharmaShots Interview: Frank Leebeek & Greta Mulder of Erasmus MC, Lutz Bonacker of CSL Behring Share Insight on Etranacogene Dezaparvovec for the Treatment of Hemophilia B

PharmaShots Interview: Frank Leebeek & Greta Mulder of Erasmus MC, Lutz Bonacker of CSL Behring Share Insight on Etranacogene Deza...

  • April 4, 2022
uniQure and CSL Behring Report Results of P-III (HOPE-B) Trial of Etranacogene Dezaparvovec for the Treatment of Hemophilia B

uniQure and CSL Behring Report Results of P-III (HOPE-B) Trial of Etranacogene Dezaparvovec for the Treatment of Hemophilia B

  • December 10, 2021
uniQure Reports 52-Week Clinical Data of Etranacogene Dezaparvovec in P-III HOPE-B Trial for Hemophilia B

uniQure Reports 52-Week Clinical Data of Etranacogene Dezaparvovec in P-III HOPE-B Trial for Hemophilia B

  • June 23, 2021
CSL Behring to Acquire uniQure' Hemophilia B Candidate (AMT-061) for ~$2B

CSL Behring to Acquire uniQure' Hemophilia B Candidate (AMT-061) for ~$2B

  • June 25, 2020
Medexus Acquires Aptevo BioTherapeutics for its Hematology Asset IXINITY

Medexus Acquires Aptevo BioTherapeutics for its Hematology Asset IXINITY

  • March 2, 2020
Novo Nordisk Reports Results of Refixia (nonacog beta pegol) in Two P-III Studies for Hemophilia B in Children

Novo Nordisk Reports Results of Refixia (nonacog beta pegol) in Two P-III Studies for Hemophilia B in Children

  • July 8, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.